Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Operating Leases: 2019-2024

Historic Operating Leases for Legend Biotech (LEGN) over the last 6 years, with Dec 2024 value amounting to $44.6 million.

  • Legend Biotech's Operating Leases rose 93.01% to $88.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.1 million, marking a year-over-year increase of 93.01%. This contributed to the annual value of $44.6 million for FY2024, which is 1.01% up from last year.
  • As of FY2024, Legend Biotech's Operating Leases stood at $44.6 million, which was up 1.01% from $44.2 million recorded in FY2023.
  • Legend Biotech's 5-year Operating Leases high stood at $44.6 million for FY2024, and its period low was $2.5 million during FY2021.
  • Its 3-year average for Operating Leases is $37.5 million, with a median of $44.2 million in 2023.
  • Per our database at Business Quant, Legend Biotech's Operating Leases plummeted by 33.31% in 2020 and then surged by 842.57% in 2022.
  • Yearly analysis of 5 years shows Legend Biotech's Operating Leases stood at $3.4 million in 2020, then decreased by 25.76% to $2.5 million in 2021, then soared by 842.57% to $23.6 million in 2022, then skyrocketed by 87.14% to $44.2 million in 2023, then grew by 1.01% to $44.6 million in 2024.